We are a biopharmaceutical company focused on harnessing powerful biology underlying major diseases to develop transformative therapeutics for patients.
We are leveraging our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines.
We aspire to operate one of our industry’s most productive research and development engines and have built a robust pipeline of drug candidates – several of which are in clinical development – to address a spectrum of large, unmet medical needs. Our initial areas of focus include cardio-metabolic, liver, oncologic and ophthalmic diseases. However, we are not limited to the therapeutic areas we can explore. We intend to continue growing our pipeline of experimental medicines.
Feb 24, 2021 11:41 AM EST
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News and Events
NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 - Virtual EditionRead more
NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and OncologyRead more
NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common StockRead more
More events are coming soon.